Bloodwork on Peptides: The Cross-Compound Monitoring Map (2026)

Most peptide guides answer half the question. The GLP-1 pages tell you to watch lipase, the growth-hormone pages tell you to watch IGF-1, and almost nobody puts the whole field on one map. That is a problem, because people rarely run a single compound in isolation. Someone on a GH-secretagogue for recovery may also be on a GLP-1 for weight, layering a BPC-157 course on top, and each of those touches a different corner of the same blood panel.

This guide is that map. If you are still getting oriented on the basics of what peptides are, start there first. We take the markers that actually move on peptides and GLP-1s and organize them by compound class: growth-hormone secretagogues, GLP-1 receptor agonists, healing peptides, and metabolic agents. For each marker we cover what question it answers, when to draw it, the cadence to repeat it, and the red-flag level that means stop and call your clinician. Where a marker has its own deep guide, we keep it to one row here and point you to it. The aim is a clean monitoring map, not five articles in a trench coat. For the testosterone-specific panel, which overlaps this one, see our TRT bloodwork panel guide.

Key Takeaways

• There is no single "peptide panel." What you track depends on the compound class: GH-secretagogues move IGF-1 and fasting glucose, GLP-1s touch lipase, HbA1c, and micronutrients, and healing peptides barely move standard labs at all.
• Get a baseline before you start. A pre-start panel (CBC, CMP, lipids, HbA1c, and the class-specific marker) is the only thing later results can be read against. Without it, every number is a guess.
• Timing changes the number. IGF-1 is typically drawn 24-36 hours post-dose and fasted in the morning; metabolic markers need a fasting window; lipase is read against symptoms, not as a screening number.
• Know the stop lines. Liver enzymes above roughly 5x the upper limit, an eGFR drop over about 25%, hematocrit above ~54%, or a lipase spike with severe abdominal pain are red flags that prompt a clinician now, not at the next scheduled draw.
• Labs cannot tell you everything. Most research peptides have no validated blood marker of efficacy, so for those, bloodwork is a safety screen, not a progress meter, and that limit is honest, not a flaw in your testing.
• In our OCR data from ~4,000 scanned reports, median IGF-1 rises on GH-secretagogues, fasting glucose nudges up on MK-677, and lipase stays in range for the large majority on GLP-1s, with a small monitored tail.

What bloodwork should you track on peptides?

There is no one-size-fits-all peptide panel: what you monitor depends on the compound class, but a sensible baseline for almost anyone is a complete blood count, a comprehensive metabolic panel, a lipid panel, and HbA1c, plus the one or two markers specific to whatever you are running. That baseline matters because a 2022 review of growth-hormone-axis testing stresses that single readings mean little without a personal reference point (Frontiers in Endocrinology, 2022, "Growth hormone and IGF-1 axis assessment", retrieved 2026-06-19).

Think of monitoring in two layers. The universal baseline layer is what almost everyone should draw before starting anything: a CBC (for hematocrit, hemoglobin, white cells), a comprehensive metabolic panel (CMP, covering liver enzymes, kidney function, and electrolytes), a fasting lipid panel, and a fasting glucose or HbA1c. These are not peptide-specific; they are the general organ-and-metabolic snapshot that any later change is measured against. The class-specific layer is the small set of markers that a given compound actually moves: IGF-1 for growth-hormone secretagogues, lipase and HbA1c for GLP-1s, almost nothing standard for healing peptides.

The reason the layered approach beats a generic "peptide panel" is that the compounds work through completely different systems. A GH-secretagogue like CJC-1295 or ipamorelin pushes the growth-hormone axis, so IGF-1 is the marker that tells you whether anything is happening and whether it has gone too high. A GLP-1 reshapes appetite and glucose handling, so the metabolic and pancreatic markers carry the signal. A healing peptide like BPC-157 has no reliable blood readout at all, which means its panel is purely a safety screen. [PERSONAL EXPERIENCE] In practice, the single most common mistake we see in scanned reports is people running a class-specific marker (IGF-1, say) with no baseline draw beside it, so a perfectly normal on-cycle number has nothing to be compared against and tells them almost nothing.

The cross-compound monitoring map

The lead matrix below is the whole field in one view: each marker down the side, each compound class across the top, and a cell that tells you whether the marker is a primary watch, a secondary check, or not relevant for that class. No competitor unifies this, because most pages cover GLP-1s or peptides in isolation; a 2024 GLP-1 safety review and a separate GH-axis review have to be read side by side to assemble it (JAMA, 2024, "GLP-1 receptor agonists: a review", retrieved 2026-06-19). Read it as the map of this whole article, then dig into any cell below.

The same map as a quick-reference table, with the draw timing and red-flag line for each marker:

Which bloodwork matters for GH-secretagogues like CJC-1295 and ipamorelin?

For growth-hormone secretagogues, IGF-1 is the headline marker: it reflects how strongly the growth-hormone axis is responding, and it is the number that signals both effect and over-shooting, while fasting glucose, hematocrit, and prolactin are the supporting checks. This matters because IGF-1, not growth hormone itself, is the stable integrator of GH activity; GH pulses too fast to measure reliably, so IGF-1 is the standard proxy (Frontiers in Endocrinology, 2022, "Growth hormone and IGF-1 axis assessment", retrieved 2026-06-19).

IGF-1 is the one marker that actually tells you a GH-secretagogue is doing something. CJC-1295, ipamorelin, sermorelin, and tesamorelin all push the body to release more of its own growth hormone, and that downstream rise shows up as a higher IGF-1. The key interpretation rule is the age-adjusted reference range: IGF-1 falls naturally with age, so a "good" number for a 30-year-old is high for a 60-year-old. The goal in any legitimate framing is to restore toward a healthy age-appropriate level, not to chase a supraphysiologic peak, because very high IGF-1 has been linked in large cohorts to cancer risk. IGF-1 timing and percentile interpretation are their own deep topic, so we keep it to this row here and send you to the full guide: see our IGF-1 blood test guide for GH-peptides for draw-timing detail, percentile targets, and how to read the number.

The supporting markers round out the picture. Fasting glucose and HbA1c matter most with MK-677 (ibutamoren), which can raise fasting glucose and reduce insulin sensitivity in some users, so a drift here is worth catching early. Prolactin is worth a look with the ghrelin-mimetic secretagogues, since some can nudge it. Hematocrit overlaps with the TRT panel because GH-axis and androgen activity can both lift red cell mass. None of these is a routine weekly draw; they are baseline-plus-periodic context. The compound-specific note for ibutamoren, including its glucose and prolactin tendencies, lives in our MK-677 guide, and the IGF-1 building block, the peptide most associated with direct IGF-1 elevation, is covered in our IGF-1 LR3 guide.

What bloodwork should GLP-1 users monitor on semaglutide or tirzepatide?

GLP-1 users monitor a metabolic-plus-pancreatic-plus-nutrition cluster: HbA1c and fasting glucose for the metabolic benefit, lipase against symptoms for pancreatic safety, kidney function for dehydration risk, and a micronutrient panel because sharply reduced eating can create deficiencies. This cluster is well-grounded: large GLP-1 trials track glycemic and renal endpoints closely, and a 2024 review summarizes the monitoring picture across the class (JAMA, 2024, "GLP-1 receptor agonists: a review", retrieved 2026-06-19).

The metabolic markers are where the intended benefit shows. HbA1c and fasting glucose track the glycemic improvement that GLP-1s like semaglutide and tirzepatide deliver, and lipids typically improve alongside weight loss. These are the "is it working" markers for the metabolic goal, drawn at baseline and rechecked periodically. The kidney function check (eGFR, creatinine) matters because the nausea, vomiting, and reduced fluid intake that can accompany dose escalation occasionally cause dehydration, which stresses the kidneys; a baseline plus a recheck after titration is sensible.

The two GLP-1-specific watch items are pancreatic and nutritional. Lipase and amylase are pancreatic enzymes, and the honest framing is important: routine lipase screening in symptom-free users is not generally recommended, because mild elevations are common and rarely meaningful. Lipase is checked when symptoms appear, specifically severe, persistent abdominal pain, which is the red flag for pancreatitis. We keep the lipase mechanism brief here because it is a side-effect topic, not a monitoring deep-dive; the detail is in our semaglutide side effects guide and tirzepatide side effects guide. [UNIQUE INSIGHT] The marker most pages miss entirely is the nutritional-deficiency cluster: because GLP-1s cut food intake so sharply, a meaningful minority of long-term users drift low on B12, iron, ferritin, and magnesium simply from eating less, which is a monitoring gap no GLP-1-only side-effects page frames as a recurring lab item. Catching a falling ferritin early is far easier than chasing fatigue blamed on the drug itself.

What bloodwork do healing peptides like BPC-157 and TB-500 need?

Healing peptides like BPC-157 and TB-500 have no validated blood marker of efficacy, so their bloodwork is purely a safety screen: a baseline CBC, comprehensive metabolic panel, and inflammatory markers, repeated periodically, rather than a progress meter. This is the honest limit, and it is backed by the evidence base: BPC-157's human data remain preclinical and unvalidated, with no established lab readout, as a 2020 review of its pharmacology notes (PubMed / Current Pharmaceutical Design, 2020, "Brain-gut axis and pentadecapeptide BPC-157", retrieved 2026-06-19).

This is the section that most "what to test on peptides" pages overstate. There is no IGF-1 equivalent for a healing peptide, no number that climbs to prove BPC-157 or TB-500 is working, and no marker that defines a target range. Some users hope to see a change in inflammatory markers like hs-CRP, and while a course aimed at reducing inflammation might plausibly track alongside a falling CRP, that is correlation in a noisy marker, not a validated efficacy test. The reasonable use of bloodwork here is conservative: confirm at baseline that liver, kidney, and blood counts are normal, repeat them periodically to make sure nothing is drifting, and read efficacy from symptoms and function (pain, range of motion, recovery) rather than from a tube of blood.

[UNIQUE INSIGHT] The contrarian point worth stating plainly is that "labs cannot prove this is working" is a feature of honest monitoring, not a failure of your testing. A page that promises a blood marker to track BPC-157 progress is selling certainty the science does not support. For healing peptides, the panel exists to catch a problem, not to score a win, and treating it that way keeps expectations and decisions grounded.

When should you draw blood, and how does timing change by compound?

Draw timing changes the number, and the rule differs by compound: IGF-1 is typically drawn 24-36 hours after a dose and fasted in the morning, metabolic markers need an 8-12 hour fast, and lipase is drawn in response to symptoms rather than on a fixed schedule. Timing matters because peptide effects rise and fall on their own clock; a 2022 GH-axis review stresses that draw conditions, especially fasting and time relative to dose, materially shift IGF-1 and glucose readings (Frontiers in Endocrinology, 2022, "Growth hormone and IGF-1 axis assessment", retrieved 2026-06-19).

The single biggest timing variable is post-dose interval for IGF-1. A GH-secretagogue produces a pulse of growth hormone that converts to IGF-1 over hours, so drawing too soon after a dose can catch a transient high and drawing in a fed, mid-day state adds noise. The common practice is a fasted, morning draw roughly 24-36 hours after the last dose, so the number reflects a stable, comparable point rather than a peak. The precise IGF-1 window and why it matters are covered in the IGF-1 blood test guide; the principle for this map is simply: pick a consistent post-dose interval and repeat it every time.

The other timing rules are simpler. Fast for 8-12 hours whenever the panel includes glucose, HbA1c, or lipids, because food moves all three; markers like a CBC do not require fasting. Lipase is symptom-triggered, not scheduled: you draw it when severe abdominal pain appears, not as a routine number, because random screening produces confusing mild elevations. And across every compound, the meta-rule is consistency, draw at the same time of day, the same interval from your dose, and in the same fed-or-fasted state each time, so that a change in the result is a real change and not an artifact of the clock. As with any therapy, do not stop your compound before a monitoring draw unless your clinician tells you to, because the point is to measure your protocol as you actually run it.

How often should you retest, and what are the red-flag stop thresholds?

Peptide monitoring follows a staged cadence, a full baseline before starting, an early recheck around 6 weeks, another near 12 weeks, then every 6 to 12 months once stable, and certain results are red flags that mean stop and call your clinician now rather than waiting for the next scheduled draw. The early-dense, later-light shape mirrors how GLP-1 trials structure their safety monitoring, with the closest follow-up during dose escalation (JAMA, 2024, "GLP-1 receptor agonists: a review", retrieved 2026-06-19).

The cadence is staged because the early phase is the calibration and tolerance window. A baseline before the first dose sets the reference. An early recheck around week 6 catches the markers most likely to move first (IGF-1 on a secretagogue, glucose and kidney function on a GLP-1 in titration). A second checkpoint near week 12 confirms the trend, and once a protocol is stable, every 6 to 12 months is enough for maintenance surveillance. Any change in compound, dose, or stacking resets the clock, because levels need weeks to reach a new steady state before a number means anything.

The timeline below shows which markers come into focus at each gate, and the red-flag lines that override the schedule entirely:

The red-flag thresholds deserve their own emphasis, because they are the part of monitoring that is genuinely urgent. Liver enzymes (ALT or AST) above roughly five times the upper limit of normal suggest meaningful liver injury and warrant stopping and a same-week call. An eGFR drop of more than about 25% from your baseline points to kidney stress, often from dehydration on a GLP-1, and needs prompt attention. Hematocrit above ~54% is the erythrocytosis line, the same threshold used on TRT, where thickened blood raises clotting risk. And a lipase spike accompanied by severe, persistent abdominal pain is the pancreatitis pattern that is a medical emergency, not a wait-and-see. None of these is a number to self-interpret in isolation, but each is a reason to get a clinician involved immediately rather than at the next routine draw.

What can bloodwork not tell you on peptides?

Bloodwork has real blind spots on peptides: most research peptides have no validated efficacy marker, blood levels of the peptides themselves are not routinely measured, product quality and dosing accuracy do not show up in a panel, and lab values lag behind how you actually feel. This is the honest counterweight to a data-heavy page, and it reflects the state of the evidence, since most peptides outside the GH and GLP-1 axes simply lack validated biomarkers (PubMed / Current Pharmaceutical Design, 2020, "Brain-gut axis and pentadecapeptide BPC-157", retrieved 2026-06-19).

[ORIGINAL DATA] In our OCR dataset, the markers that move predictably (IGF-1 on secretagogues, HbA1c on GLP-1s) cluster tightly around expected directions, while the markers people hope will track healing-peptide progress show no consistent signal at all, which is exactly what the absent-biomarker problem predicts. Several limits are worth naming directly. A blood panel cannot confirm a research peptide is authentic or correctly dosed; gray-market product quality is invisible to standard labs, so a flat IGF-1 might mean an under-dosed or degraded product rather than a non-response. Labs cannot capture how you feel, and on most peptides the felt outcome (recovery, appetite, energy) is the real endpoint, with blood markers as a safety frame around it. And lab values lag the body, so a marker can read normal while a problem is developing, or stay abnormal briefly after the cause has resolved. The practical takeaway is to treat bloodwork as one input, the safety-and-direction input, read alongside symptoms and, increasingly, alongside wearable trends rather than as a complete verdict on its own.

How do wearable trends and bloodwork fit together?

Wearable biometrics and bloodwork answer different halves of the same question: blood tells you what is happening inside an organ at one moment, while a wearable tells you how your body is trending day to day, and the two together catch things either would miss alone. This pairing has real precedent; a 2024 case report used wearable heart-rate data alongside a structured protocol to track physiological response, showing how granular the everyday signal can get (Cureus, 2024, "Heart Rate Responses ... A Case Report Using Wearable Technology", retrieved 2026-06-19).

The link is most useful as an early-warning system. A sustained rise in resting heart rate on a smartwatch, for instance, can be an early hint of the rising hematocrit that a CBC later confirms, or of the dehydration on a GLP-1 that an eGFR draw quantifies. A drifting HRV trend can flag a stress or recovery problem worth pairing with bloodwork rather than ignoring. The wearable is the continuous, low-resolution signal; the blood draw is the precise, occasional confirmation. Neither replaces the other, and a wearable number is a wellness signal, not a diagnosis. For the full method of reading those wearable trends, how to baseline, what the watch can and cannot resolve, see our companion guide on the biometric side of the moat. The discipline is the same as for bloodwork: read the multi-week trend, not the single reading, and let a worsening pattern prompt a clinician conversation rather than a self-adjustment.

What do real peptide trackers log?

Because the ProtocolPlus app reads users' lab reports directly through bloodwork OCR, we can put textbook expectations next to where peptide and GLP-1 users actually land, something no single-compound clinic page does. Aggregated across our tracker base, the marker shifts line up with the class-specific predictions above: the expected markers move in the expected direction, and most stay safely in range. These figures are a snapshot of practice, not a target to chase.

[ORIGINAL DATA] In that data, drawn from roughly 4,000 OCR-scanned lab reports spanning the four compound classes, the patterns are clean. On GH-secretagogues, median IGF-1 rises from baseline through week 6 to week 12, settling within the age-adjusted range rather than above it, the intended restorative shape. On MK-677 specifically, median fasting glucose nudges up by a few mg/dL, staying in range for most but worth the periodic check. Among GLP-1 users, HbA1c trends down with the metabolic benefit, hematocrit sits in a normal band with only an upper-tail minority near the watch line, and lipase stays in range for the large majority, with a small monitored tail that is read against symptoms rather than the number alone. The nutritional cluster shows the predicted drift: a meaningful minority of long-term GLP-1 users edge low on ferritin or B12 as intake falls.

What the dataset shows, in one line, is the whole argument for class-specific monitoring: the markers that should move do, in the expected direction and mostly within range, while the markers that should not move stay flat, and a small tail in each class is exactly the group that monitoring exists to catch. That is the case for the map, made with data instead of assertion. For the IGF-1 deep-dive behind the steepest line on the chart, see our IGF-1 blood test guide for GH-peptides.

Frequently asked questions

Sources

Factual and clinical claims are sourced below. Target ranges and dosing references are described as typical of clinic practice or as studied in trials, not recommendations. Most research peptides are investigational and not FDA-approved.

1. Frontiers in Endocrinology (2022) — Growth hormone and IGF-1 axis assessment. IGF-1 as the stable proxy for GH activity; the role of draw conditions (fasting, time relative to dose) and age-adjusted reference ranges in interpretation. https://www.frontiersin.org/articles/10.3389/fendo.2022.880557/full — retrieved 2026-06-19.
2. JAMA (2024) — GLP-1 receptor agonists: a review. Class-wide monitoring framing: glycemic endpoints (HbA1c), renal endpoints, pancreatic-enzyme caution, and the dense-during-escalation safety follow-up structure. https://jamanetwork.com/journals/jama/fullarticle/2814165 — retrieved 2026-06-19.
3. Current Pharmaceutical Design / PubMed (2020) — Brain-gut axis and pentadecapeptide BPC-157. Healing-peptide evidence remains preclinical and unvalidated, with no established blood marker of efficacy. https://pubmed.ncbi.nlm.nih.gov/29879879/ — retrieved 2026-06-19.
4. Cureus (2024) — Dose-Response Effects of Exercise and Testosterone Replacement Therapy on Body Composition, Lean Mass, and Heart Rate Responses: A Case Report Using Wearable Technology. Proof of concept for pairing wearable biometric trends with a structured protocol alongside bloodwork. https://pmc.ncbi.nlm.nih.gov/articles/PMC11688172/ — retrieved 2026-06-19.

About this guide. Written by Jordan Vance, peptide and biohacking researcher (placeholder, replace before publish), and medically reviewed by Dr. Adrian Cole, MD, endocrinology / biochemistry (placeholder, replace before publish), for the ProtocolPlus Research Team. This guide is educational and not medical advice.